Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines und Revolution Medicines kündigen Zusammenarbeit bei klinischer Entwicklung und regionaler Vermarktung an

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines and Revolution Medicines have announced a multi-faceted collaboration aimed at advancing clinical development and regional marketing of targeted therapies for RAS-dependent cancers. This partnership leverages the strengths of both companies in oncology, potentially benefiting patients with these specific cancer types.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to enhance clinical development.
  • Partnership focuses on targeted therapies for RAS-dependent cancers.
  • Both companies are well-established in oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
lenvatinib
Phase 2 · Advanced Solid Tumor

Full Press Release Details

SAN CARLOS und REDWOOD CITY, Kalifornien, USA--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, und Revolution Medicines, Inc. (Nasdaq: RVMD), ein Onkologieunternehmen mit Wirkstoffen in der späten klinischen Entwicklung, das zielgerichtete Therapien für Patienten mit RAS-abhängigen Krebserkrankungen entwickelt, gaben heute eine mehrteilige Zusammenarbeit bekannt. Diese umfasst eine klinische Zusammenarbeit zur Bewertung v

Frequently Asked Questions

What companies are collaborating in this announcement?

BeOne Medicines and Revolution Medicines are collaborating.

What is the focus of the collaboration?

The collaboration focuses on clinical development and regional marketing of targeted therapies.

What type of cancers are targeted in this partnership?

The partnership targets RAS-dependent cancers.

What is BeOne Medicines known for?

BeOne Medicines is an oncology company involved in global operations.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines Revolution Medicines oncology RAS-dependent cancers clinical development
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
lenvatinibPhase 2
Advanced Solid Tumor →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →